| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Cristina Mega | Q85378759 |
| Flávio Reis | Q38545312 | ||
| Rosa Fernandes | Q47503161 | ||
| Edite Teixeira De Lemos | Q64190488 | ||
| P2093 | author name string | Cristina Mega | |
| Rosa Fernandes | |||
| Edite Teixeira-de-Lemos | |||
| P2860 | cites work | Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition | Q84658993 |
| Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes | Q84782119 | ||
| Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat | Q86037160 | ||
| Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats | Q86231620 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin | Q24642412 | ||
| A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists | Q26744229 | ||
| Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes? | Q26745523 | ||
| Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? | Q26745606 | ||
| Dynamic pathology of islet endocrine cells in type 2 diabetes: β-Cell growth, death, regeneration and their clinical implications | Q26752746 | ||
| Incretin-Based Therapy for Prevention of Diabetic Vascular Complications | Q26765470 | ||
| Dipeptidyl peptidase-4 and kidney fibrosis in diabetes | Q26766089 | ||
| Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control | Q26766259 | ||
| Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials | Q26772068 | ||
| The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review | Q26774377 | ||
| Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? | Q26777994 | ||
| The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease | Q26784454 | ||
| DPP4 in Diabetes | Q26797335 | ||
| Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance and β-Cell Dysfunction | Q26800081 | ||
| Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus | Q26829529 | ||
| Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure | Q26829634 | ||
| Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells | Q79717077 | ||
| Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats | Q82186212 | ||
| Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level | Q83565130 | ||
| Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level | Q83572227 | ||
| Tubular biomarkers to assess progression of diabetic nephropathy | Q83993834 | ||
| Tribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetes | Q84453183 | ||
| The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms | Q37562145 | ||
| Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes | Q37598881 | ||
| Tubulointerstitial disease in diabetic nephropathy | Q37669397 | ||
| The beta-cell in human type 2 diabetes. | Q37706253 | ||
| Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties | Q37720797 | ||
| Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals | Q37725539 | ||
| The physiologic role of incretin hormones: clinical applications. | Q37728788 | ||
| Pharmacokinetics of dipeptidylpeptidase-4 inhibitors | Q37768821 | ||
| Oxidative stress in early diabetic nephropathy: fueling the fire | Q37820092 | ||
| Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence | Q37900690 | ||
| Diabetic neuropathy: cellular mechanisms as therapeutic targets | Q37930962 | ||
| Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome | Q37942524 | ||
| Choosing a gliptin | Q37949599 | ||
| Recent advances in incretin-based therapies | Q38026956 | ||
| Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research | Q38040596 | ||
| Physiology and pathophysiology of incretins in the kidney | Q38164490 | ||
| The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? | Q38174491 | ||
| Sitagliptin: a review of its use in patients with type 2 diabetes mellitus | Q38177173 | ||
| Extra-pancreatic effects of incretin-based therapies | Q38194069 | ||
| Clinical review of sitagliptin: a DPP-4 inhibitor | Q38207620 | ||
| Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials | Q38219234 | ||
| Diabetic nephropathy and inflammation | Q38220820 | ||
| The potential for renoprotection with incretin-based drugs | Q38227648 | ||
| Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors | Q38248682 | ||
| The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. | Q38253620 | ||
| DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease | Q38376373 | ||
| Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease | Q38436685 | ||
| The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? | Q38527885 | ||
| 1. Strategies for Improving Care | Q38676992 | ||
| Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy | Q38831478 | ||
| Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study | Q38906591 | ||
| DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control | Q38922177 | ||
| Understanding the cardiovascular effects of incretin. | Q39260864 | ||
| Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin | Q27023789 | ||
| Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity | Q27315825 | ||
| Advanced glycation end products and diabetic complications | Q27687501 | ||
| Update on the treatment of type 2 diabetes mellitus | Q28073342 | ||
| Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction | Q28237208 | ||
| Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects | Q28252893 | ||
| Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus | Q28253541 | ||
| Oxidative stress as a major culprit in kidney disease in diabetes | Q28281957 | ||
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | Q28285795 | ||
| Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms | Q28535415 | ||
| c-Abl mediates angiotensin II-induced apoptosis in podocytes | Q28571893 | ||
| Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats | Q28583508 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| The Role of Overweight and Obesity in the Cardiorenal Syndrome | Q30411964 | ||
| Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway | Q30445160 | ||
| Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future | Q30597265 | ||
| Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications | Q31104386 | ||
| Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives | Q31121965 | ||
| Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. | Q33271012 | ||
| Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease | Q33580624 | ||
| Pathogenesis of diabetic nephropathy | Q33585821 | ||
| Prevention of obesity-induced renal injury in male mice by DPP4 inhibition | Q33610654 | ||
| Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms | Q33865096 | ||
| The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus | Q33891620 | ||
| The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. | Q33932817 | ||
| Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) | Q34003019 | ||
| Oxidative stress and metabolic pathologies: from an adipocentric point of view. | Q34038044 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| Update on developments with SGLT2 inhibitors in the management of type 2 diabetes | Q34198692 | ||
| DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat | Q34270500 | ||
| The biology of incretin hormones | Q34499706 | ||
| Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor | Q34579106 | ||
| DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes | Q37095161 | ||
| Impaired tubular uptake explains albuminuria in early diabetic nephropathy | Q37123261 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes | Q37221770 | ||
| Podocytes: the Weakest Link in Diabetic Kidney Disease? | Q37340690 | ||
| Pathogenic perspectives for the role of inflammation in diabetic nephropathy. | Q37387708 | ||
| Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study | Q37403310 | ||
| The role of reactive oxygen species in apoptosis of the diabetic kidney. | Q37494545 | ||
| Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors | Q37527141 | ||
| Beta cell dysfunction and insulin resistance | Q39325879 | ||
| Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. | Q39613724 | ||
| Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice | Q39797395 | ||
| Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice | Q39975807 | ||
| Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats | Q40756554 | ||
| Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial | Q40944104 | ||
| Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells. | Q41051941 | ||
| The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice | Q41849344 | ||
| Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies | Q41966262 | ||
| Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure. | Q42050075 | ||
| Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. | Q42149619 | ||
| Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? | Q42175983 | ||
| Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis | Q42542336 | ||
| Role of the renin angiotensin system in diabetic nephropathy | Q42723231 | ||
| Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats | Q43191012 | ||
| Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes | Q43274458 | ||
| Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. | Q43592968 | ||
| Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs | Q43651817 | ||
| Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes | Q43972608 | ||
| Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes | Q44403823 | ||
| Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats | Q44460517 | ||
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q45212807 | ||
| Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate | Q45361069 | ||
| Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin | Q46120204 | ||
| Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy. | Q46506887 | ||
| A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. | Q46774459 | ||
| Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy | Q46870214 | ||
| Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes | Q47361701 | ||
| Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. | Q50271509 | ||
| Serine proteases, inhibitors and receptors in renal fibrosis. | Q50357092 | ||
| Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy. | Q50782080 | ||
| Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. | Q50928745 | ||
| Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. | Q51307150 | ||
| Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. | Q51333357 | ||
| A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. | Q51350351 | ||
| Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. | Q51364785 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
| Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. | Q51743180 | ||
| Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition. | Q52954535 | ||
| Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress. | Q53062551 | ||
| Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. | Q53207032 | ||
| Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats. | Q53558949 | ||
| GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. | Q54513292 | ||
| Pathologic classification of diabetic nephropathy. | Q55052603 | ||
| Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. | Q55118966 | ||
| Erratum. Microvascular Complications and Foot Care. Sec. 10. In Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1);S88-S98. | Q55407485 | ||
| Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism | Q58335889 | ||
| Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow | Q58447525 | ||
| The Role of Transforming Growth Factor-Beta in Diabetic Nephropathy | Q59048778 | ||
| Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats | Q61952009 | ||
| Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model | Q61952011 | ||
| Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat | Q74082999 | ||
| Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease | Q74246043 | ||
| Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule | Q74599385 | ||
| Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice | Q34597496 | ||
| New paradigms in cell death in human diabetic nephropathy | Q34622431 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice | Q34718822 | ||
| Novel functions of the CD34 family | Q34873662 | ||
| Inflammatory cytokines in diabetic nephropathy. | Q35133177 | ||
| Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes | Q35179865 | ||
| NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia | Q35193553 | ||
| Recent advances in diabetic nephropathy | Q35520625 | ||
| Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). | Q35607330 | ||
| Mechanisms Linking Inflammation to Insulin Resistance | Q35744922 | ||
| Lifestyle change and mobility in obese adults with type 2 diabetes | Q35919090 | ||
| Management of Hyperglycemia in Diabetic Kidney Disease | Q35953856 | ||
| Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations | Q36064147 | ||
| Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects | Q36170755 | ||
| Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis | Q36589609 | ||
| Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial | Q36625527 | ||
| DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid | Q36639293 | ||
| Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus | Q36693199 | ||
| Effect of GLP-1 Receptor Activation on Offspring Kidney Health in a Rat Model of Maternal Obesity | Q36719266 | ||
| beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
| Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency | Q36782645 | ||
| Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes | Q36822640 | ||
| Podocyte biology in diabetic nephropathy | Q36891952 | ||
| The role of protein kinase C activation in diabetic nephropathy | Q36891957 | ||
| Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules | Q36939370 | ||
| Diabetes mellitus as a cause of end-stage renal disease in Europe: signs of improvement | Q36951243 | ||
| Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats | Q36965895 | ||
| Metabolomics in diabetic complications | Q37041169 | ||
| New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond | Q37069916 | ||
| Islet inflammation in type 2 diabetes: from metabolic stress to therapy. | Q37069944 | ||
| The TRIB3 Q84R polymorphism and risk of early-onset type 2 diabetes | Q37072688 | ||
| The role of inflammatory cytokines in diabetic nephropathy. | Q37078749 | ||
| Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy | Q37084522 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dipeptidyl peptidase-4 inhibitors | Q419770 |
| diabetic nephropathy | Q1129105 | ||
| type 2 diabetes | Q3025883 | ||
| mechanism of action | Q3271540 | ||
| protective agent | Q50380088 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 5164292 | |
| P577 | publication date | 2017-08-27 | |
| P1433 | published in | Journal of Diabetes Research | Q26841822 |
| P1476 | title | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes | |
| P478 | volume | 2017 |
| Q57477167 | Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes |
| Q58695035 | Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling |
| Q92406505 | Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study |
| Q57179232 | Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition |
| Q64111503 | Sitagliptin protects against hypoxia/reoxygenation (H/R)-induced cardiac microvascular endothelial cell injury |
| Q92282014 | The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin |
| Q61814333 | Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes |
Search more.